Yazar "Salva, E." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Actively targeted chitosan-based vector for efficient CRISPR-Cas9 mediated Tenascin-C gene editing in triple negative breast cancer(Mary Ann Liebert, Inc, 2021) Bareke, H.; Fuentes, M.; Oladipo, A. A.; Ozbas, S.; Salva, E.[Abstract Not Available]Öğe Comparison of short and long siVEGF/encapsulating chitosan nanoparticles in breast cancer cell lines(Mary Ann Liebert, Inc, 2016) Comez, B.; Akbuga, J.; Salva, E.[Abstract Not Available]Öğe The investigation of effects to cell proliferation and adsorption of new ternary and binary scaffolds(Mary Ann Liebert, Inc, 2016) Sirkeci, A.; Salva, E.; Turan, S. O.; Akbuga, J.[Abstract Not Available]Öğe The silencing of PDGF-B pathway by Chitosan/siRNA nanoplexes in therapy of the experimental mesangial proliferative glomerulonephritis(Mary Ann Liebert, Inc, 2016) Salva, E.; Alan, S.; Yilmaz, I.; Turan, S. O.; Akbuga, J.[Abstract Not Available]Öğe Synthesis, anticancer activity and ADMET studies of N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-[(3-substituted)ureido/thioureido] benzenesulfonamide derivatives(Taylor & Francis Ltd, 2018) Karakus, S.; Tok, F.; Tuerk, S.; Salva, E.; Tatar, G.; Taskin-Tok, T.; Kocyigit-Kaymakcioglu, B.A series of novel 4-[(3-substituted)ureido]-N-(5-methyl-1,3,4-thiadiazol-2-yl) benzenesulfonamides and 4-[(3-substituted)thioureido]-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamides were prepared from 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (sulfamethizole). The structures of the synthesized compounds were determined by IR, H-1-NMR, MS and elemental analysis. The anticancer activity of these compounds was evaluated against human colorectal carcinoma (HCT116) and human cervix carcinoma (HeLa) cell lines. Compound 4 (4-{[(2,4-dichlorophenyl)carbamoyl]amino}-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide) showed marked anticancer activity, being the most active compounds in this series with the IC50 value of 13.92 +/- 0.22 mu M and 37.91 +/- 0.10 mu M against HeLa and HCT116, respectively. In silico, ADMET was used to examine their pharmacokinetic properties. ADMET (absorption, distribution, metabolism, excretion, and toxicity) studies were applied to develop new anticancer compound(s) with high selectivity. [GRAPHICS] .Öğe Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats(Taylor & Francis Ltd, 2013) Elcioglu, H. K.; Kabasakal, L.; Alan, S.; Salva, E.; Tufan, F.; Karan, M. A.Neuroinflammatory responses caused by amyloid beta (A beta) peptide deposits are involved in the pathogenesis of Alzheimer's disease (AD). Thalidomide has a significant anti-inflammatory effect by inhibiting TNF-alpha, which plays role in A beta neurotoxicity. We investigated the effect of thalidomide on AD-like cognitive deficits caused by intracerebroventricular injection of streptozotocin (STZ). Intraperitoneal thalidomide was administered 1 h before the first dose of STZ and continued for 21 days. Learning and memory behavior was evaluated on days 17, 18 and 19, and the rats were sacrificed on day 21 to examine histopathological changes. STZ injection caused a significant decrease in the mean escape latency in passive avoidance and decreased improvement of performance in Morris water maze tests. Histopathological changes were examined using hematoxylineosin and Bielschowsky staining. Brain sections of STZ treated rats showed increased neurodegeneration and disturbed linear arrangement of cells in the cortical area compared to controls. Thalidomide treatment attenuated significantly STZ induced cognitive impairment and histopathological changes. Thalidomide appears to provide neuroprotection from the memory deficits and neuronal damage induced by STZ.
